XNCR - Xencor, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
33.44
-0.83 (-2.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close34.27
Open34.17
Bid0.00 x 800
Ask0.00 x 800
Day's Range33.05 - 34.51
52 Week Range27.75 - 48.38
Volume89,655
Avg. Volume224,843
Market Cap1.884B
Beta (3Y Monthly)0.73
PE Ratio (TTM)48.46
EPS (TTM)0.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.80
Trade prices are not sourced from all markets
  • Business Wire1 hour ago

    Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein, Ph.D., as vice president, business development. Dr. Grunstein brings more than 15 years of expertise in partnering, acquisitions and licensing in the biopharmaceutical industry and will lead strategic partnering to enhance the development of Xencor’s pipeline of drug candidates.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Xencor Inc.

    Xencor Inc NASDAQ NMS:XNCRView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for XNCR with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 15. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding XNCR is favorable, with net inflows of $3.64 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Xencor Inc Earnings Call

  • Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript
    Motley Fool13 days ago

    Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript

    XNCR earnings call for the period ending March 31, 2019.

  • Associated Press14 days ago

    Xencor: 1Q Earnings Snapshot

    On a per-share basis, the Monrovia, California-based company said it had profit of $1.38. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Business Wire14 days ago

    Xencor Reports First Quarter 2019 Financial Results

    -- Management to Host Conference Call at 4:30 p.m. ET today --

  • Business Wire15 days ago

    Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc.  , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and alle

  • Business Wire17 days ago

    Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the first patient has been dosed in XmAb23104-01 (DUET-3), a Phase 1 clinical study to evaluate the safety and tolerability of XmAb23104, a bispecific antibody that simultaneously targets the immune receptors PD-1 and ICOS, for the treatment of patients with advanced solid tumors.

  • Business Wire21 days ago

    Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019

    Xencor, Inc.  , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release first quarter 2019 financial results after the market closes on Thursday, May 9, 2019.

  • Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount?
    Simply Wall St.22 days ago

    Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In this article we are going to estimate the intrinsic value of Xencor, Inc. (NASDAQ:XNCR) by ta...

  • Business Wire23 days ago

    Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that was placed on the Phase 1 study of XmAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia and other CD123-expressing hematologic malignancies. “We are working with investigational sites to resume enrollment based on the amended protocol, through which we have sought to enhance the safety of patients participating in the study,” said Paul Foster, M.D., senior vice president and chief medical officer at Xencor.

  • Here’s What Hedge Funds Think About Xencor Inc (XNCR)
    Insider Monkey23 days ago

    Here’s What Hedge Funds Think About Xencor Inc (XNCR)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Business Wire2 months ago

    Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology. Xencor and Astellas will collaborate to generate bispecific antibodies directed toward a selected anti-tumor target for the potential treatment of patients with cancer, and Astellas will have an exclusive worldwide license to develop and commercialize novel drug candidates.

  • Business Wire2 months ago

    Xencor to Participate in Upcoming Investor Conferences

    Xencor, Inc.  , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and alle

  • Why I Like Xencor, Inc. (NASDAQ:XNCR)
    Simply Wall St.2 months ago

    Why I Like Xencor, Inc. (NASDAQ:XNCR)

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Xencor, Inc. (NASDAQ:XNCR) is a company with exceptional fundamental characteristics. Upon building up an investment...

  • Business Wire2 months ago

    Xencor Announces Closing of Research Collaboration and License Agreement with Genentech

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research collaboration and license agreement with Genentech, a member of the Roche Group, following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. Xencor and Genentech entered the agreement to develop and commercialize novel IL-15 cytokine therapeutics, including XmAb®24306, an IL-15/IL-15Rα cytokine complex engineered with Xencor’s bispecific Fc domain and Xtend™ Fc technology.

  • GlobeNewswire3 months ago

    New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Is Xencor, Inc.’s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers?
    Simply Wall St.3 months ago

    Is Xencor, Inc.’s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers?

    In 2005 Bassil Dahiyat was appointed CEO of Xencor, Inc. (NASDAQ:XNCR). First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snapRead More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of XNCR earnings conference call or presentation 25-Feb-19 9:30pm GMT

    Q4 2018 Xencor Inc Earnings Call

  • Zacks3 months ago

    Too Much Talking, Not Enough Action

    Too Much Talking, Not Enough Action

  • GuruFocus.com3 months ago

    Xencor Inc (XNCR) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Xencor Inc (NASDAQ:XNCR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.